FDA reviewers voice concerns over hypoglycemia with Novo Nordisk weekly insulin

hapabapa

U.S. FDA scientists said that there is a risk that Novo Nordisk’s (NVO) once-weekly insulin icodec, under investigation for type 1 and type 2 diabetes, can lead to extremely low blood sugar levels.

In briefing documents released Wednesday in advance


Source link
Exit mobile version